Global Oncolytic Virus Therapies Market By Virus (Genetically Engineered Oncolytic Viruses, Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Oncolytic Wild-Type Viruses, Reovirus, Others), By Application (Solid Tumors, Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, Melanoma, Others), By End-User (Hospitals, Specialty Clinics, Cancer Research Institutes), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

Oncolytic Viruses (OV) are those viruses that will selectively eliminate lysis cancerous tissue while causing no harm to healthy tissue. Oncolytic viral therapy is a type of immunotherapy in which the patient’s immune system is activated to identify cancer cells as “foreign tissue.” It is the use of replication-competent viruses for the treatment of cancer.

While chemo and radiation therapy are still the most popular forms of cancer treatment, their substantial side-effects are an immense disadvantage. Biological therapy for cancer, despite its complexity and difficulty, is the favoured treatment option due to its high efficacy, fewer side effects, and reduced discomfort for cancer patients. So far clinical trials report no deaths or serious adverse events attributed to oncolytic virus therapies. The safety of cancer patients is important, and treatment using oncolytic viruses appears to be the most promising in this regard.

Detailed Segmentation:

The global oncolytic virus therapies market is segmented on the basis of – Virus Type, Application, End-Use, and Region.

Based on Virus Type

• Genetically Engineered Oncolytic Viruses
• Herpes Simplex Virus
• Adenovirus
• Vaccinia Virus
• Oncolytic Wild-Type Viruses
• Reovirus
• Newcastle Disease Virus
• Vesicular Stomatitis Virus

Based on Application

• Solid Tumors
• Breast Cancer
• Prostate Cancer
• Lung Cancer
• Glioblastoma
• Melanoma
• Hematological Malignancies
• Lymphoma
• Leukemia
• Myeloma

Based on End-Use

• Hospitals
• Specialty Clinics
• Cancer Research Institutes

Based on Regions

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics

Oncolytic Viral Therapy (OVT) has a number of benefits, including increased killing efficiency, precise targeting, and lesser side-effects or drug resistance. Increased cancer prevalence globally has boosted the demand for oncolytic viral medicines, which is projected to boost revenue growth prospects for this market in the future. Other key factors expected to complement market growth include advancements in research technologies, development of cost-effective therapies and robust pipeline projects, increased government investments to boost cancer research, as well as increased awareness concerning the benefits of an early diagnosis.

However, developing an OV that meets all or at least many of the parameters required for broad spectrum cancer treatment remains extremely challenging. There are a number of viral therapy treatment options available, each one offering unique advantages as well as drawbacks in terms of therapy. As a result, finding a single OV with broad spectrum infectivity of cancer cell is extremely difficult.

OV developers likewise face a scarcity of development, scaling-up, and commercialization of resources. Because all viruses operate differently, knowledge on how to manipulate and develop them is necessary. In addition to all of this, clinical trials pose a significant hurdle. Owing to the novelty of this modality, there are many aspects of OV trial development that require in-depth optimization.

Thus, higher costs associated with research & development activities as well as certain side effects associated with therapy, are some key factors that may hamper market growth prospects to a significant extent over the forecast period.

Key Players:

• Oncolytics Biotech Inc.
• Amgen Inc.
• Sorrento Therapeutics Inc.
• Transgene S.A.
• Daiichi Sankyo Company
• Shanghai Sunway Biotech Co. Ltd.
• Takara Bio Inc.
• PsiOxus Therapeutics Ltd.
• SillaJen Inc.
• ViroCure
• Other Key Players

Recent Developments

• In April 2021, Bristol Myers Squibb and PsiOxus Therapeutics Ltd. expanded their partnership to study PsiOxus Therapeutics Cancer-killing Virus. Under the agreement, the partnership will combine Bristol’s checkpoint inhibitor Opdivo, and new asset HG-641, with different types of tumors.
• In January 2021, Enara Bio and Boehringer Ingelheim announced a strategic collaboration and licensing agreement for R&D of novel targeted cancer immunotherapy. The new collaboration combines Boehringer’s approach to treat cancer through pairing science with innovative platforms such as oncolytic virus and cancer vaccines, with Enara’s expertise in cancer antigen identification

For the Oncolytic Virus Therapies Market research study, the following years have been considered to estimate the market size: